Please use this identifier to cite or link to this item:
Title: Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission
Authors: Scott C. Olson
Nicole Ngo-Giang-Huong
Ingrid Beck
Wenjie Deng
Paula Britto
David E. Shapiro
Roger E. Bumgarner
James I. Mullins
Russell B. Van Dyke
Gonzague Jourdain
Lisa M. Frenkel
Keywords: Immunology and Microbiology
Issue Date: 31-Jul-2015
Abstract: Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. To prevent mother-to-child-transmission of HIV-1, the 2010 WHO guidelines recommended prenatal zidovudine (ZDV) monotherapy (option A). To determine if ZDV monotherapy selects for HIV resistance in antiretroviral-naive women during pregnancy, specimens from 50 individuals were examined using pyrosequencing. ZDVresistance mutations were detected at delivery in seven women (14%, 95% confidence interval 6.6-26.5%). These data raise the question whether women administered ZDV monotherapy for prevention of mother-to-child-transmission could have higher risk of virologic failure when later started on combination antiretroviral therapy, as has been demonstrated following single-dose nevirapine prophylaxis.
ISSN: 14735571
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.